Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Ovarian cancer, version 3.2012.

Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA; National Comprehensive Cancer Network..

J Natl Compr Canc Netw. 2012 Nov 1;10(11):1339-49.

PMID:
23138163
2.

Ovarian cancer: a focus on management of recurrent disease.

Herzog TJ, Pothuri B.

Nat Clin Pract Oncol. 2006 Nov;3(11):604-11. Review.

PMID:
17080178
3.

[Treatment of epithelial ovarian cancer].

Langmár Z, Csömör S.

Orv Hetil. 2006 Aug 27;147(34):1627-32. Review. Hungarian.

PMID:
17017677
4.

New developments in the management of ovarian cancer.

Hoskins WJ.

J Med Assoc Ga. 2003 Winter-Spring;92(1):23-6, 33. Review. No abstract available.

PMID:
12743902
5.

Diagnosis and management of epithelial ovarian cancer.

Bhoola S, Hoskins WJ.

Obstet Gynecol. 2006 Jun;107(6):1399-410. Review.

PMID:
16738170
6.

Recent advances in the management of women with ovarian cancer.

Eltabbakh GH.

Minerva Ginecol. 2004 Feb;56(1):81-9. Review.

PMID:
14973412
7.

The changing landscape of therapeutic strategies for recurrent ovarian cancer.

Baumann KH, Wagner U, du Bois A.

Future Oncol. 2012 Sep;8(9):1135-47. doi: 10.2217/fon.12.112. Review.

PMID:
23030488
8.

[Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].

du Bois A, Lück HJ, Meerpohl HG.

Zentralbl Gynakol. 1997;119(7):299-323. Review. German.

PMID:
9340970
9.

[Treatment of ovarian cancer].

Cianti C.

Clin Ter. 2002 Mar-Apr;153(2):135-44. Review. Italian.

PMID:
12078339
10.

NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.

Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff AC; National Comprehensive Cancer Network..

J Natl Compr Canc Netw. 2006 Mar;4 Suppl 1:S1-26. Review.

PMID:
16507275
11.

Pursuit of optimum outcomes in ovarian cancer: methodological approaches to therapy.

Gibbs DD, Gore ME.

Drugs. 2001;61(8):1103-20. Review.

PMID:
11465872
12.

New issues in systemic therapy for ovarian cancer.

Armstrong DK.

J Natl Compr Canc Netw. 2013 May;11(5 Suppl):690-3. Review.

PMID:
23704245
13.

Recurrent ovarian cancer: when and how to treat.

Hall M, Rustin G.

Curr Oncol Rep. 2011 Dec;13(6):459-71. doi: 10.1007/s11912-011-0199-3. Review.

PMID:
22045509
14.

The current treatment of recurrent ovarian cancer.

Herzog TJ.

Curr Oncol Rep. 2006 Nov;8(6):448-54. Review.

PMID:
17040623
15.

An overview of current diagnosis and treatment in ovarian cancer.

Mould T.

Int J Gynecol Cancer. 2012 May;22 Suppl 1:S2-4. doi: 10.1097/IGC.0b013e318251c8e3. Review. No abstract available.

PMID:
22543914
16.

Gynecological malignancies.

Schaebler DL, Schilder RJ, Young RC.

Cancer Chemother Biol Response Modif. 1996;16:564-91. Review.

PMID:
8639401
17.

The management of recurrent ovarian cancer.

Bukowski RM, Ozols RF, Markman M.

Semin Oncol. 2007 Apr;34(2 Suppl 2):S1-15. Review. No abstract available.

PMID:
17512352
18.

The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer.

Weinberg LE, Rodriguez G, Hurteau JA.

J Surg Oncol. 2010 Mar 15;101(4):334-43. doi: 10.1002/jso.21482. Review.

PMID:
20187069
19.

Oncology today: ovarian cancer.

Tiedemann D.

RN. 2000 Oct;63(10):36-41; quiz 42. Review.

PMID:
11062665
20.

A systematic overview of chemotherapy effects in ovarian cancer.

Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care..

Acta Oncol. 2001;40(2-3):340-60. Review.

PMID:
11441940

Supplemental Content

Support Center